Zynyz (retifanlimab)
- Region
- 🇪🇺 EU
- Active substance
- retifanlimab
- Company
- Incyte Biosciences Distribution B.V.
- Status
- Application withdrawn
- Therapeutic area
- Anus Neoplasms; Carcinoma, Squamous Cell
- Application
- EMEA/H/C/005632
- ATC
- L01FX06
- Official record
- www.ema.europa.eu
Indication
Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Zynyz Authorised · Incyte Biosciences Distribution B.V.
Follow Zynyz
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.